Efficacy of artesunate-amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in mainland Tanzania.
| dc.contributor.author | Mwaiswelo, Richard O. | |
| dc.date.accessioned | 2024-04-05T11:21:32Z | |
| dc.date.available | 2024-04-05T11:21:32Z | |
| dc.date.issued | 2024-03-29 | |
| dc.description.abstract | Background: Diversification of artemisinin-based combination therapy (ACT) is suggested as one of the strategies that can be used to contain artemisinin resistance. Artesunate-amodiaquine (ASAQ) is one of the artemisinin-based combinations that can be used in the diversification strategy as an alternative first-line treatment for uncomplicated malaria in mainland Tanzania. There is however limited data on the efficacy of ASAQ in mainland Tanzania. This study assessed the efficacy of ASAQ for treatment of uncomplicated Plasmodium falciparum malaria in selected sentinel sites for therapeutic efficacy studies in mainland Tanzania. Methods: Between December 2018 and March 2020, children aged between 6 months and 10 years, attending at Nagaga, Mkuzi, and Mlimba primary health facilities, and with suspected uncomplicated malaria infection were screened for eligibility to participate in the study. Malaria infection was screened using microscopy. Children with uncomplicated P. falciparum monoinfection and who fulfilled all other inclusion criteria, and had none of the exclusion criteria, according to the World Health Organization (WHO) guidelines, were treated with ASAQ. Follow-up visits were scheduled on days 0, 1, 2, 3, 7, 14, 21, and 28 or on any day of recurrent infection for clinical and laboratory assessment. Polymerase chain reaction (PCR)-corrected cure rate on day 28 was the primary outcome. Results: A total of 264 children, 88 in each of the three study sites (Mlimba, Mkuzi and Nagaga health facilities) were enrolled and treated with ASAQ. The ASAQ PCR-corrected cure rate was 100% at all the three study sites. None of the participants had early treatment failure or late clinical failure. Furthermore, none of the participants had a serious adverse event. Conclusion: ASAQ was highly efficacious for the treatment of uncomplicated P. falciparum malaria in mainland Tanzania, therefore, it can be deployed as an alternative first-line treatment for uncomplicated malaria as part of diversification strategy to contain the spread of partial artemisinin resistance in the country. | en_US |
| dc.identifier.citation | Ngasala, B., Bushukatale, S., Chiduo, M., Makene, T., Mkony, L., Mohamed, A., Molteni, F., Chacky, F., Njau, R.J. and Mwaiswelo, R., 2024. Efficacy of artesunate-amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in mainland Tanzania. Malaria Journal, 23(1), p.90. | en_US |
| dc.identifier.other | DOI https://doi.org/10.1186/s12936-024-04923-0 | |
| dc.identifier.uri | http://hdl.handle.net/123456789/1329 | |
| dc.language.iso | en | en_US |
| dc.publisher | Malaria Journal | en_US |
| dc.subject | Artesunate-amodiaquine | en_US |
| dc.subject | Plasmodium falciparum malaria | en_US |
| dc.subject | Mainland Tanzania | en_US |
| dc.title | Efficacy of artesunate-amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in mainland Tanzania. | en_US |
| dc.type | Article | en_US |